ReviewCold Spring Harbor perspectives in medicine2012
Fluid biomarkers in Alzheimer disease.
Review in Cold Spring Harbor perspectives in medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 1 synthesis or guideline pooled it.
- To Keto or Not to Keto? A Systematic Review of Randomized Controlled Trials Assessing the Effects of Ketogenic Therapy on Alzheimer Disease.Advances in nutrition (Bethesda, Md.) · 2020Pooled it
- Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors.Alzheimer's research & therapy · 2016Trial
- Disease progression modeling of Alzheimer's disease based on variational probability principal component analysis.PloS one · 2026Article
- Proteome-Based Biomarkers for Alzheimer's Disease: Old Acquisitions and Innovative Proposals.International journal of molecular sciences · 2025Review
- MS4A6A/Ms4a6d deficiency disrupts neuroprotective microglia functions and promotes inflammation in Alzheimer's disease model.Molecular neurodegeneration · 2025Article
- Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia-specific perspectives.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- MRI-based Alzheimer's disease classification using Vision Transformer and time-series transformer: A step-by-step guide.Software impacts · 2025Article
- Separating dementia with Lewy bodies from Alzheimer's disease dementia using a volumetric MRI classifier.European radiology · 2025Article
- Computational Risk Stratification of Preclinical Alzheimer's in Younger Adults.Diagnostics (Basel, Switzerland) · 2025Article
- Accelerated Alzheimer's Aβ-42 secondary nucleation chronologically visualized on fibril surfaces.Science advances · 2024Article
- Clinical Application of Blood Biomarkers in Neurodegenerative Diseases-Present and Future Perspectives.International journal of molecular sciences · 2024Review
- SIMOA Diagnostics on Alzheimer's Disease and Frontotemporal Dementia.Biomedicines · 2024Article
- The Cerebrospinal Fluid Free-Glycans HexBiomolecules · 2024Article
- Joint transformer architecture in brain 3D MRI classification: its application in Alzheimer's disease classification.Scientific reports · 2024Article
- Differential patterns of lysosomal dysfunction are seen in the clinicopathological forms of primary progressive aphasia.Journal of neurology · 2024Article
- A Critical Analysis of the FDA's Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Mild traumatic brain injury as a pathological process.Heliyon · 2023Review
- Intersectionality in Alzheimer's Disease: The Role of Female Sex and Black American Race in the Development and Prevalence of Alzheimer's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Review
- Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit.Alzheimer's research & therapy · 2023Article
- The Association of Kidney Function with Plasma Amyloid-β Levels and Brain Amyloid Deposition.Journal of Alzheimer's disease : JAD · 2023Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research progress has provided detailed understanding of the molecular pathogenesis of Alzheimer disease (AD). This knowledge has been translated into new drug candidates with putative disease-modifying effects, which are now being tested in clinical trials. The promise of effective therapy has created a great need for biomarkers able to detect AD in the predementia phase, because drugs will probably be effective only if neurodegeneration is not too advanced. In this chapter, cerebrospinal fluid (CSF) and plasma biomarkers are reviewed. The core CSF biomarkers total tau (T-tau), phosphorylated tau (P-tau) and the 42 amino acid form of β-amyloid (Aβ42) reflect AD pathology, and have high diagnostic accuracy to diagnose AD with dementia and prodromal AD in mild cognitive impairment cases. The rationale for the use of CSF biomarkers to identify and monitor the mechanism of action of new drug candidates is also outlined in this chapter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.